The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders

Jurjen J. Luykx

doi:10.1016/j.euroneuro.2022.07.003

The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	46-48
Number of pages	3
Journal	European Neuropsychopharmacology
Volume	62
DOIs	https://doi.org/10.1016/j.euroneuro.2022.07.003
Publication status	Published - Sept 2022

Keywords

Antipsychotic Agents
Humans
Psychotic Disorders

Access to Document

10.1016/j.euroneuro.2022.07.003

Cite this

@article{ac6dc7b04edb4beea47461fe8fbadc06,

title = "The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders",

keywords = "Antipsychotic Agents, Humans, Psychotic Disorders",

author = "Luykx, \{Jurjen J.\}",

year = "2022",

month = sep,

doi = "10.1016/j.euroneuro.2022.07.003",

language = "English",

volume = "62",

pages = "46--48",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

}

TY - JOUR

T1 - The future of antipsychotics studies

T2 - How innovative designs may benefit patients with psychotic disorders

AU - Luykx, Jurjen J.

PY - 2022/9

Y1 - 2022/9

KW - Antipsychotic Agents

KW - Humans

KW - Psychotic Disorders

UR - https://www.scopus.com/pages/publications/85134976043

U2 - 10.1016/j.euroneuro.2022.07.003

DO - 10.1016/j.euroneuro.2022.07.003

M3 - Article

C2 - 35896056

AN - SCOPUS:85134976043

SN - 0924-977X

VL - 62

SP - 46

EP - 48

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders

Keywords

Access to Document

Other files and links

Cite this